A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

So, what's the tea on microdosing? It's pretty much what it sounds like — taking smaller doses than the usual prescribed ...

Methods: This study was a retrospective, single-center study in which outpatients with T2DM were 1) aged 20 years or older at the time of oral semaglutide administration, 2) treated with an existing ...

2 If approved, Wegovy ® would become the first oral formulation of a GLP-1 indicated for chronic weight management. "We are entering a new era of obesity care where patients want individualized ...

The explosion of compounded GLP-1 offerings over the past two years is ... Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators ...

However, emerging research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists ... Medications such as semaglutide (Ozempic) and tirzepatide (Mounjaro), which affect appetite and ...

The meteoric rise of the drug semaglutide (marketed as Ozempic or Wegovy ... The study concerned users of GLP-1 medications—such as Ozempic, Mounjaro, Trulicity, and Wegovy—and their food choices.

A new clinical trial led by researchers at the University of North Carolina School of Medicine has revealed that the oral form of semaglutide (GLP-1) significantly reduces the risk of heart ...

Many of the first shedders to get their hands on GLP-1 drugs like Ozempic and Mounjaro, are reaching the end of their weight-loss journey and preparing to transition away from them. This is opening ...

Mounjaro: Contains Tirzepatide, a dual GLP-1 and GIP receptor agonist. Ozempic: Contains Semaglutide, a GLP-1 receptor agonist. Mounjaro is not Insulin, it is a type of drug called a dual glucose ...